Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

BRBrian D. RossYJYoungsoon JangHKHasaruwani Kiridena

Discussion

Loading...

Member takes

Overview

Observational analysis lowered splenic volume in a mouse model of myelofibrosis, suggesting combination therapy improves outcomes.

Key Points

  • Combination therapy lowered spleen size in a mouse model of myelofibrosis, and improved survival metrics after treatment.
  • Mean spleen volume significantly decreased in the combination therapy group, achieving a reduction to 16.1 mm3/BW.
  • Analysis of spleen samples highlighted effective modulation of fibrosis and survival signals with combination therapy.
  • This approach may enable a novel therapeutic strategy for myelofibrosis, enhancing treatment efficacy and patient outcomes.

Cite This Study

Ross et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5d2https://doi.org/10.1182/blood-2025-4329
View Full Paper
Ask AI
Bookmark
Share